Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOCLEAR-200 vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
FDA: Treatment of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life: ~8 hours (range 3–12 hours) in adults; prolonged in hepatic impairment, heart failure, COPD, and neonates. Significantly shorter in smokers (4–6 hours).
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Hepatic via CYP1A2, CYP2E1, and CYP3A4. Follows Michaelis-Menten kinetics with dose-dependent metabolism.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination; metabolites (caffeine, 3-methylxanthine, 1-methyluric acid) excreted renally. Fecal excretion negligible.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
~40% bound, primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3–0.7 L/kg; approx. 0.45 L/kg in adults. Increased Vd in premature infants, cirrhosis, and CHF. Distributes freely into breast milk and across placenta.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 96% (nearly complete). Rectal: variable (70–90%). Intravenous: 100%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No specific GFR-based dose adjustments are recommended; however, monitor serum theophylline concentrations in patients with renal impairment as clearance may be reduced.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: avoid use or use with extreme caution; monitor serum levels frequently. Dose adjustments should be guided by serum theophylline concentrations.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Initial dose: 5 mg/kg orally every 6 hours (immediate-release) or 10-15 mg/kg/day divided every 12 hours (extended-release). Titrate based on serum theophylline levels (target 5-15 mcg/m L). Maximum dose: 16 mg/kg/day up to 400 mg/day for children 1-9 years; 16 mg/kg/day up to 600 mg/day for children 9-16 years.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lowest effective dose (e.g., 200 mg once daily) and titrate slowly. Monitor serum theophylline concentrations closely due to reduced clearance in elderly. Target serum level: 5-10 mcg/m L.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
None
None.
Narrow therapeutic index; serum levels must be monitored to avoid toxicity.,Use with caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias.,Coadministration with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, macrolides) can alter theophylline clearance.,May cause tachycardia, palpitations, and central nervous system stimulation.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation.
Hypersensitivity to theophylline or any component of the formulation.
Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it can potentiate side effects. Food does not significantly alter absorption, but take with food if gastrointestinal upset occurs. Charcoal-broiled foods may increase metabolism; maintain consistent intake.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
FDA Pregnancy Category C. First trimester: Crosses placenta; limited data suggest no major malformations but fetal tachycardia and jitteriness reported. Second and third trimesters: Risk of neonatal apnea, hypoglycemia, and hypocalcemia due to beta-adrenergic stimulation. Avoid during labor due to risk of maternal tachycardia and fetal distress.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Excreted in breast milk; milk-to-plasma ratio approximately 0.6-0.7. Considered compatible with breastfeeding but monitor infant for irritability, insomnia, and tachycardia. Accumulation may occur in neonates with reduced clearance.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Increase dose by 20-30% in second and third trimesters due to increased clearance and volume of distribution. Monitor levels frequently; postpartum return to prepregnancy dosing within 2 weeks.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theophylline has a narrow therapeutic index (5-15 mcg/m L); levels >20 mcg/m L increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or fever, as clearance is reduced. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; monitor levels and adjust dose. Smoking induces metabolism; require higher doses. Consider drug interactions with CYP1A2 inhibitors/inducers. Serum theophylline levels should be monitored at steady state and with any change in medication or condition.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take THEOCLEAR-200 exactly as prescribed; do not change dose without consulting your doctor.,Do not crush or chew sustained-release tablets; swallow whole.,Avoid large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects.,Inform your doctor if you experience nausea, vomiting, insomnia, tremors, or rapid heartbeat.,Do not smoke or start/stop smoking without telling your doctor, as it affects theophylline levels.,Keep all appointments for blood tests to monitor theophylline levels.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOCLEAR-200 vs AEROLATE JR, answered by our medical review team.
THEOCLEAR-200 is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOCLEAR-200 and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOCLEAR-200 is: Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOCLEAR-200 and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOCLEAR-200 is classified as Category C. FDA Pregnancy Category C. First trimester: Crosses placenta; limited data suggest no major malformations but fetal tachycardia and jitteriness reported. Second and third trimesters. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.